UCB reported EUR1.57B in Cash and Equivalent for its fiscal semester ending in December of 2024.





Cash And Equivalent Change Date
Alcon AG USD 1.58B 80M Mar/2026
Almirall EUR 337.77M 14.83M Dec/2025
Amarin USD 131.06M 3.6M Mar/2026
argenx SE USD 4.3B 808.71M Mar/2026
AstraZeneca USD 7.56B 1.85B Mar/2026
Bayer EUR 6.67B 774M Dec/2025
Genmab DKK 1.72B 46M Dec/2025
GlaxoSmithKline GBP 3.44B 292M Mar/2026
GRIFOLS EUR 801M 242.31M Dec/2025
Hikma Pharmaceutical USD 236M 48M Jun/2025
Lakefront Biotherapeutics EUR 66.8M 21.06M Mar/2026
Lonza CHF 719M 188M Dec/2025
Merck EUR 2.33B 77M Dec/2025
Novartis USD 6.88B 4.56B Mar/2026
Orion EUR 160.9M 63.3M Dec/2025
Recordati EUR 428.82M 42.64M Dec/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 7.66B 1.25B Dec/2025
UCB EUR 1.57B 1.14B Dec/2024
Unibail Rodamco EUR 5.29B 668.7M Dec/2024